Optibiotix Health Share Discussion Threads

[shrewdmole] 04/6/2018 11:26

Nobby

Exactly! Spot on.

Many years ago I was lucky enough to correspond with a former MM for a while and there are a few real tell tale signs.

Today is one of them. They opened the spread right up to try and deter or slow down the buying but they keep being hit for 15,25,60k when they actually want sellers.


I strongly suspect winterfloods are either short or have an order to fill as like you say you can sell decent size above mid price but try buying!

S

[elrico] 04/6/2018 11:24

Parob - It will be interesting to see how both the business develops and if investors are attracted to OPTI as an investment vehicle. Seed could be a litmus test for the form and the latter.

Most of Sunday I plodding along setting up a blog, which has only been up 7 hours when I grab the following stats; which I'm sure most of you won't be impressed with the numbers, but the geographical spread is interesting.

United Kingdom 296

Czechia 44

Germany 42

United States 37

Ireland 21

France 19

Spain 8

Australia 4

India 2

Italy 2

[nobbygnome] 04/6/2018 11:18

Currently 72.55 bid in reasonable size so the 70p on the screen is a false reflection of the MMs position. Why doesn't one of the MMs move to 72p? I guess you have to assume that they are short and so are reluctant to move up because that would be more likely to encourage buyers than sellers.

[parob] 04/6/2018 11:11

It will be interesting to see if the Seed launch brings in new US investors.

[shrewdmole] 04/6/2018 11:06

67k showing on here too.

Some real traction taking place now the big boys want a piece.

[zebbo] 04/6/2018 11:06

Does look like the MMs are short and will need to balance the books at some point. Could pop at any time in order to shake out some sellers. Doubt they will want to be short for long

[rafboy] 04/6/2018 10:51

Someone just bought over 60k shares on Nex.

[parob] 04/6/2018 10:47

Per status update on LinkedIn over the weekend. We have developed a Prebiotic "LPGOS" that helps lowering Cholesterol and in combination with our Probiotic strain LPLDL triples the cholesterol reducing effect in Gut models. LPGOS is a Prebiotic that can be added into every day foods and opens up a new and exciting opportunity to apply healthy cholesterol management and reduction through your daily diet. As part of the development we have industrial scale up agreement in place with Tata Chemicals in India and we are now in the early discussions with partners that can help develop the applications and with companies that have the ability and reach to take LPGOS into the global food manufactures.......Very Exciting times ahead for LPGOS !! #cholesterol #foodmanufacturing #prebiotic #health hTtp://optibiotix.com/optibiotix-to-present-lpgos-study-results-at-ipc2018/

[pj 1] 04/6/2018 10:44

LOL, my standards are slipping!

[someuwin] 04/6/2018 10:42

Can buy £1k online. But not £2k.

[jestercat2] 04/6/2018 10:42

PJ1 - you were spot on

[slartybartfaster] 04/6/2018 10:38

Be careful PJ you have a rep to live up to. :D

[pj 1] 04/6/2018 10:23

Certainly looks as if they will have to raise the bid.

[aspex] 04/6/2018 10:21

Yes, the MMs are buying in stock at increasing prices which all looks very positive.

[shrewdmole] 04/6/2018 09:32

Jester

There's definitely a different feel to Opti this last few days and some very chunky trades.


S

[jestercat2] 04/6/2018 09:27

50K buy at 73p. Looks like OPTI might have legs today.

[nobbygnome] 04/6/2018 09:00

😂😂😂

[bobdown2] 04/6/2018 08:56

Thanks Belgrono2...lettuce continue....

[belgrano2] 04/6/2018 08:53

There was an iceberg seller on Friday which did not show. Seems order is complete, and upward movement now can continue.

[shrewdmole] 04/6/2018 08:48

160,000 shares at 70p

Either a delayed buy or MM happy to take the sell of that size on at no discount.

Very positive.

[nobbygnome] 04/6/2018 08:47

I have a theory as to why we didn't get a large rise on Friday in the face of sustained buying. The new shares can be traded today and the MMs thought their short position would be filled by a deluge of sells from the placees. However, I suspect most like me will be holding their shares for a much higher price and there won't be much selling in reality. So if this is true, we could get a good rise in the next few days.

Nobby

[rafboy] 04/6/2018 08:32

They just widened the spread, to put of buyers?

[parob] 04/6/2018 08:31

Are we gonna break through 75p this week?Seed launch should help!

[dire cons] 04/6/2018 07:51

Apologies if posted here previously. C & p from ii

OptiBiotix Health - investors like what they see; The latest fundraiser underscores the fact the life sciences business is well supported in the City

[...]

" In the last year, it has inked a deal with an offshoot of Premier Foods that makes Angel Delight

The fact its latest share issue was keenly priced and yet still over-subscribed, tells you all you need to know about OptiBiotix Health PLC (LON:OPTI).

Investors like the business, which is using its expertise in the human microbiome to develop food additives and pharmaceutical products that tackle ailments and diseases of our era – obesity, high cholesterol and diabetes.

Proceeds from the £1.5mln placing, conducted at a modest discount to last night’s close, will be used to super-charge progress.

It follows hard on the heels of a series of deals that will help propel the business forward commercially. And this progress is at the heart of why OptiBiotix is tapping investors for cash.


READ: Today's news in full

One of the opportunities open to the business is to develop cholesterol buster LPLDL as a pharmaceutical as well as food additive.

Potential partners are willing to fund regulatory submissions and clinical studies, but OptiBiotix will be required to invest in developing process controls and quality procedures.

The cash injection will also be used to fully exploit opportunities for sweetener SweetBiotix and to promote SlimBiome, its weight loss product.

"The company has received a high level of partner interest in its technology and products across new application areas and territories that have the potential for significant value uplift," said chief executive Stephen O'Hara.

"It has become clear that new opportunities, particularly the development of LPLDL into a pharmaceutical product, the high level of corporate interest in SweetBiotix across multiple applications, and the potential for listing a range of health and wellbeing products with major retailers are not achievable in the short term within current resources.


No delay to opportunities

"Rather than delay these opportunities until OptiBiotix has sufficient revenues to cover costs, the Board has decided to take additional funds to capitalise on these growth opportunities and build shareholder value.

"Whilst the subscription was oversubscribed the company has limited the funds received to ensure a focus on value creation and has added new institutional investors to the share register."

As mentioned above, OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

After spinning off its SkinBio business as a separately-listed entity last year, the group is now focused on three development areas referred to above – cholesterol, diabetes and weight loss.


Transition made

In the last year, it has inked a deal with an offshoot of Premier Foods that makes Birds Custard, Indian giant Tata and Seed Health in the US.

finnCap, the OptiBiotix’s corporate broker, has been impressed with progress made by CEO O’Hara and his expanded commercial team.

Analyst Mark Brewer in a note to clients pointed out the group has transitioned from being technology-focused to one that inked 16 commercial agreements last financial year and this.

“This significantly de-risks the business,” he added Brewer.

“The focus for the current year will be to begin to convert these agreements into revenues; the timing and quantum of which remains difficult to forecast.” "